Latin America Fabry Disease Treatment Market to Reach USD 164.68 Million by 2034, Growing at a CAGR of 6.6%

Polaris Market Research analyzes the Latin America Fabry disease treatment market to register a CAGR of 6.6% during 2025-2034. The market was valued at USD 81.36 million in 2024. It is projected to grow to USD 164.68 million by 2034.

Market Introduction
Fabry disease treatment aims to address the underlying enzyme deficiency and manage the symptoms of this rare genetic disorder. Fabry disease is caused by a lack of or malfunctioning of the enzyme alpha-galactosidase A. The lack of the enzyme leads to the buildup of a fatty substance called globotriaosylceramide (GL-3 or Gb3) in various cells of the body. The main treatment for Fabry disease is enzyme replacement therapy (ERT). In ERT, patients receive biweekly intravenous infusions of synthetic alpha-galactosidase A to help reduce the accumulation of GL-3 and slow disease progression. Another option is chaperone therapy, which helps stabilize the body's own enzymes, allowing them to function properly. In addition to disease-specific treatments, patients often require symptomatic management, including medications for pain, gastrointestinal symptoms, and heart complications.

Get Exclusive Sample Pages of This Report:
https://www.polarismarketresearch.com/industry-analysis/latin-america-fabry-disease-treatment-market/request-for-sample

Market Key Players
The competitive landscape of the Latin America Fabry disease treatment market market is defined by active market expansion strategies and an increase in cross-border collaborations. Industry analysis reveals an increasing number of strategic alliances between regional institutions and global biotech innovators. A few of the major market participants include:

• Chiesi Farmaceutici S.p.A.
• JCR Pharmaceuticals Co., Ltd.
• Protalix BioTherapeutics Inc.
• Sanofi
• Takeda Pharmaceutical

Latin America Fabry Disease Treatment Market Report Highlights

By route of administration, in 2024, the intravenous route segment was valued at USD 129 million and dominated the market revenue share due to its continued role as the primary method of delivering enzyme replacement therapy for Fabry disease.

Based on therapy, in 2024, the enzyme replacement therapy (ERT) segment was valued at approximately USD 135 million. The segment led the market revenue share driven by its established clinical efficacy and long-standing use in Fabry disease management.

The Brazil Fabry disease treatment market accounts for approximately 40% of the total regional revenue. The market growth is largely attributed to a combination of advanced healthcare access in major cities and government support for rare disease initiatives.

The Argentina Fabry disease treatment market is projected to register a CAGR of 6.5% from 2025 to 2034, fueled by a rising focus on rare disease detection and enhanced collaboration between public healthcare bodies and global pharmaceutical developers.

Market Growth Drivers
Rising Awareness of Rare Diseases: Educational campaigns focused on rare diseases are playing an increasingly pivotal role in driving awareness about Fabry disease in Latin America. Advocacy groups, along with medical associations, are conducting outreach programs and digital awareness drives that help individuals recognize early symptoms of the disease.

Growth in Urban Healthcare Infrastructure: Major cities across Latin America are witnessing a significant expansion in healthcare infrastructure. This improves access to rare disease treatments, such as those needed for Fabry disease. Hospitals in urban areas across Mexico, Brazil, and Argentina are increasingly equipped with advanced diagnostic technologies and specialized treatments, making it easier for patients to receive proper diagnosis and consistent treatment.

Request for a Discount on this Report Before Purchase:
https://www.polarismarketresearch.com/industry-analysis/latin-america-fabry-disease-treatment-market/request-for-discount-pricing

Market Segmentation
Latin America Fabry disease treatment Market, Route of Administration Outlook (Revenue - USD Million, 2020-2034)
• Intravenous Route
• Oral Route

Latin America Fabry disease treatment Market, Therapy Outlook (Revenue - USD Million, 2020-2034)
• Enzyme Replacement Therapy (ERT)
• Substrate Reduction Therapy (SRT)
• Others

Latin America Fabry disease treatment Market, Distribution Channel Outlook (Revenue - USD Million, 2020-2034)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Explore The Complete Comprehensive Report Here:
https://www.polarismarketresearch.com/industry-analysis/latin-america-fabry-disease-treatment-market
Country Analysis

Brazil: Brazil accounts for over 40% of the total regional revenue, driven by the presence of advanced healthcare access in major cities and government support for initiatives addressing rare diseases. Rising investments in healthcare in Brazil are also contributing to the increased availability of Fabry disease treatment in the country.

Argentina: Argentina is projected to register a CAGR of 6.5% during the projection period. This is largely due to the growing focus on detecting rare diseases and increased collaboration between public healthcare bodies and global pharmaceutical companies. The rising availability of enzyme replacement therapy and substrate reduction therapy supports a more structured treatment pathway in the region.

More Trending Latest Reports by Polaris Market Research:
Cardiology Ehr Market
https://www.polarismarketresearch.com/industry-analysis/cardiology-ehr-market

Aseptic Connectors & Welders Market
https://www.polarismarketresearch.com/industry-analysis/aseptic-connectors-and-welders-market

U.S. AAMI Level 3 Surgical Gown Market
https://www.polarismarketresearch.com/industry-analysis/us-aami-level-3-surgical-gown-market

U.S. DNA Manufacturing Market
https://www.polarismarketresearch.com/industry-analysis/us-dna-manufacturing-market

DNA Manufacturing Market
https://www.polarismarketresearch.com/industry-analysis/dna-manufacturing-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.